Ellen M. Langer

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Ellen Langer, Ellen M Langer, Ellen Marie Langer
Publication record
49 papers · 1,832 citations · H-index 15

PAPERS

Abstract A031: Interrogating microenvironmental changes that impact early pancreatic cancer development
20250 citationsauthor #6
Abstract C102: Investigating rapid metastatic recurrence of pancreatic cancer after resection in a novel, immune-competent, Myc-dependent murine model
20240 citationsauthor #6
Abstract B028: Fibroblast PIN1 regulates growth factor and metabolic crosstalk to impact a subset of pancreatic cancer cells
20240 citationsauthor #8
Patient-Derived Models of Cancer in the NCI PDMC Consortium: Selection, Pitfalls, and Practical Recommendations
20243 citationsauthor #7
Abstract A061: A novel genetically engineered mouse model of Myc-driven pancreatic cancer recapitulates phenotypic heterogeneity, metastasis, and therapy resistance seen in clinical populations
20240 citationsauthor #24
Abstract 4217: An engineered breast tumor microenvironment model, with single-cell spatial resolution, to assess spatial dynamics of tumor evolution
20240 citationsauthor #4
Abstract PR012: A novel, immune-competent, Myc-dependent murine model of rapid metastatic recurrence of pancreatic cancer after resection
20230 citationsauthor #5
MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer
202315 citationsauthor #21
Abstract LB161: Single cell bioprinted cell circuits for the systematic assessment of cell-cell communication in the early tumor microenvironment
20230 citationsauthor #5
Micelle-Formulated Juglone Effectively Targets Pancreatic Cancer and Remodels the Tumor Microenvironment
202311 citationsauthor #14
Abstract 880: MYC drives phenotypic heterogeneity, metastasis, and therapy resistance in pancreatic ductal adenocarcinoma
20220 citationsauthor #12
Ongoing Replication Stress Response and New Clonal T Cell Development Discriminate Between Liver and Lung Recurrence Sites and Patient Outcomes in Pancreatic Ductal Adenocarcinoma
20221 citationsauthor #6
Abstract C056: The prolyl isomerase PIN1 controls fibroblast state plasticity to impact pancreatic cancer
20220 citationsauthor #1
Abstract A067: Myc drives phenotypic heterogeneity, metastasis, and therapy resistance in pancreatic ductal adenocarcinoma
20220 citationsauthor #12
Abstract PO-061: Myc drives phenotypic heterogeneity, metastasis, and therapy resistance in pancreatic ductal adenocarcinoma
20210 citationsauthor #11
Abstract LT012: The prolyl isomerase PIN1 plays a critical role in fibroblast plasticity to impact pancreatic cancer
20211 citationsauthor #1
Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo
2021109 citationsauthor #11
Abstract PO-113: The prolyl isomerase PIN1 plays a critical role in fibroblast differentiation states to support pancreatic cancer
20210 citationsauthor #1
The Prolyl Isomerase PIN1 Plays a Critical Role in Fibroblast Differentiation States to Support Pancreatic Cancer
20210 citationsauthor #1
Sulfopin, a selective covalent inhibitor of Pin1, blocks Myc-driven tumor initiation and growth in vivo
20207 citationsauthor #8
Altering MYC phosphorylation in the epidermis increases the stem cell population and contributes to the development, progression, and metastasis of squamous cell carcinoma
202014 citationsauthor #2
Integrated Single-Cell Analysis Reveals Treatment-Induced Epigenetic Homogenization
20201 citationsauthor #2
Data-Driven Identiﬁcation of Cancer Cell Population Dynamics Leveraging the Effect of Pre-Treatment for Drug Schedule Design
20200 citationsauthor #4
PIN1 Provides Dynamic Control of MYC in Response to Extrinsic Signals
202013 citationsauthor #3
Abstract IA-06: Heterotypic 3D bioprinted tissues to study pancreatic cancer
20200 citationsauthor #1
Abstract A27: Heterotypic 3D bioprinted tissues to interrogate tumor-microenvironment crosstalk in cancer
20200 citationsauthor #1
Correction: Modeling differentiation-state transitions linked to therapeutic escape in triple-negative breast cancer
20190 citationsauthor #4
Abstract I16: KRAS and environmental signals regulate MYC to drive lineage plasticity, pancreas cancer progression, and therapeutic resistance
20190 citationsauthor #1
Modeling differentiation-state transitions linked to therapeutic escape in triple-negative breast cancer
201918 citationsauthor #4
Modeling Tumor Phenotypes In Vitro with Three-Dimensional Bioprinting
2019198 citationsauthor #1
Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity.
201938 citationsauthor #11
Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer
2018142 citationsauthor #2
On the Analysis of Cyclic Drug Schedules for Cancer Treatment using Switched Dynamical Systems
201811 citationsauthor #3
The tumor suppressor phosphatase PP2A-B56α regulates stemness and promotes the initiation of malignancies in a novel murine model
201718 citationsauthor #2
ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells
201757 citationsauthor #1
Abstract B51: Modeling the intrinsic and extrinsic influences on breast cancer phenotypic heterogeneity using mouse models and three-dimensional bioprinting
20161 citationsauthor #1
Abstract B52: Overcoming phenotypic heterogeneity and plasticity in basal-like breast cancer through targeting adaptive pathway use
20160 citationsauthor #2
Abstract 1631: FGF2 activation of FGFR1 in head and neck squamous cell carcinoma is associated with more invasive disease and can be attenuated by FGFR inhibition
20161 citationsauthor #5
Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer
2014174 citationsauthor #7
Abstract LB-222: Differentiation state heterogeneity in breast cancer and its role in therapeutic response
20140 citationsauthor #3
Dual actions of Meis1 inhibit erythroid progenitor development and sustain general hematopoietic cell proliferation.
201257 citationsauthor #2
Snail and the microRNA-200 Family Act in Opposition to Regulate Epithelial-to-Mesenchymal Transition and Germ Layer Fate Restriction in Differentiating ESCs
201179 citationsauthor #2
Mesp1 coordinately regulates cardiovascular fate restriction and epithelial-mesenchymal transition in differentiating ESCs.
2008213 citationsauthor #4
Ajuba LIM proteins are snail/slug corepressors required for neural crest development in Xenopus.
2008119 citationsauthor #1
The LIM Protein AJUBA Recruits Protein Arginine Methyltransferase 5 To Mediate SNAIL-Dependent Transcriptional Repression
2008228 citationsauthor #5
The Ajuba LIM domain protein is a corepressor for SNAG domain mediated repression and participates in nucleocytoplasmic Shuttling.
200763 citationsauthor #6
Nucleocytoplasmic Shuttling Mediated Repression and Participates in − Domain The Ajuba LIM Domain Protein Is a Corepressor for SNAG
20070 citationsauthor #6
The role of Ajuba LIM proteins in the nucleus
20070 citationsauthor #1
Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage.
2002240 citationsauthor #5

TIMELINE

2002 240 citations

2007 63 citations

2008 560 citations

2011 79 citations

2012 57 citations

2014 174 citations

2016 2 citations

2017 75 citations

2018 153 citations

2019 254 citations

2020 35 citations

2021 110 citations

2022 1 citations

2023 26 citations

2024 3 citations

2025 0 citations

Ellen M. Langer

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT